Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Harmalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 3/20 | 0.68 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.64 |
| ▸ | HTR7 known ✓ | P34969 | 4/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.64 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.64 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.64 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.64 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.64 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.62 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.62 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.62 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.48 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.38 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.38 |
| ▸ | PRKD1 known ✓ | Q15139 | 1/20 | 0.36 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CASP1 | P29466 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Harmalol SCHEMBL18489068 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL30285851 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL2516758 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL555401 | 0.97 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL30163266 | 0.97 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL7669597 | 0.91 | KDM4E (0.87) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| SCHEMBL1520498 | 0.86 | KDM4E (0.79) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmalol SCHEMBL9480810 | 0.85 | KDM4E (0.77) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmaline SCHEMBL30055802 | 0.81 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 | |
| Harmaline SCHEMBL177545 | 0.81 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2022-03-08 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-5657064-A | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5635322-A | Process for developing and overcoating migration imaging members | XEROX CORPORTION (US) | 1997-06-03 | — | — | US | disclosed |
| US-5580689-A | SOLFTENABLE LAYER OF SOFTENABLE MATERIAL, PIGMENT SENSITIVE TO INFRARED OR RED LIGHT ILLUMINATION, AND MIGRATION MARKING MATERIAL | XEROX CORPORATION (US) | 1996-12-03 | — | — | US | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5534374-A | Migration imaging members | XEROX CORPORATION (US) | 1996-07-09 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0673782-A2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266634-B2 | Methods for treating melanoma with human therapeutic agents | HNMT, INMT, TYR | GLA 1456/4885HTR2C 141/4885HTR7 139/4885 |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | GLA 2811/4885HTR2C 583/4885HTR7 904/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | GLA 1840/4885HTR2C 74/4885HTR7 76/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | GLA 2679/4885HTR2C 128/4885HTR7 125/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GLA 1840/4885HTR2C 74/4885HTR7 76/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | GLA 1840/4885HTR2C 74/4885HTR7 76/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | GLA 2340/4885HTR2C 346/4885HTR7 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.